GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » Net Margin %

Quanterix (Quanterix) Net Margin %

: -39.78% (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Quanterix's Net Income for the three months ended in Dec. 2023 was $-12.4 Mil. Quanterix's Revenue for the three months ended in Dec. 2023 was $31.2 Mil. Therefore, Quanterix's net margin for the quarter that ended in Dec. 2023 was -39.78%.

The historical rank and industry rank for Quanterix's Net Margin % or its related term are showing as below:

QTRX' s Net Margin % Range Over the Past 10 Years
Min: -131.78   Med: -83.8   Max: -26.69
Current: -26.69


QTRX's Net Margin % is ranked worse than
63.94% of 818 companies
in the Medical Devices & Instruments industry
Industry Median: 0.045 vs QTRX: -26.69

Quanterix Net Margin % Historical Data

The historical data trend for Quanterix's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quanterix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -71.91 -39.43 -54.76 -92.14 -26.69

Quanterix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.55 -21.62 -19.64 -25.16 -39.78

Competitive Comparison

For the Medical Devices subindustry, Quanterix's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quanterix Net Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Quanterix's Net Margin % distribution charts can be found below:

* The bar in red indicates where Quanterix's Net Margin % falls into.



Quanterix Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Quanterix's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-32.334/121.139
=-26.69 %

Quanterix's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-12.409/31.197
=-39.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quanterix  (NAS:QTRX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Quanterix Net Margin % Related Terms

Thank you for viewing the detailed overview of Quanterix's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Quanterix (Quanterix) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlesex Turnpike, Billerica, MA, USA, 01821
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.
Executives
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly director C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram officer: Chief Financial Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser director 561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle officer: CFO and Treasurer C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue officer: President, Quanterix & Dx C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka director 2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
John J Fry officer: General Counsel & Secretary 8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky director, officer: EC, President & CEO 68 ELM STREET, HOPKINTON MA 01748
Karen Flynn director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy officer: SVP R&D and CTO C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon officer: Sr VP, Stgc Mrktg & Assay Tech 113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421